News Releases

Date Title and Summary
Toggle Summary electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar
ROCKAWAY, NJ , April 20, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East Agency to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve
Toggle Summary electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
ROCKAWAY, NJ , April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs.
Toggle Summary electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance
First-quarter 2021 revenue expected to be more than $1.1 million Net cash used for the first quarter 2021 of approximately $4.1 million   ROCKAWAY, NJ , April 13, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an
Toggle Summary electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment ROCKAWAY, NJ , April 08, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1
Toggle Summary electroCore, Inc. Announces Regulatory Approval in Canada
ROCKAWAY, NJ , April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Canada for prevention
Toggle Summary electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe
ROCKAWAY, N.J. , March 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Silvert Medical Nv-Sa. (“Silvert Medical”) whereby Silvert Medical will serve as the exclusive distributor
Toggle Summary Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms
ROCKAWAY, N.J. --(BUSINESS WIRE)--Mar. 15, 2021-- Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC . Peter Staats , M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with
Toggle Summary electroCore Announces Fourth Quarter and Full Year 2020 Financial Results
Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019 Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020 Ended 2020 with cash and cash equivalents of $22.6 million , excluding
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2020 Financial Results on Thursday, March 11
Conference Call to be Held at 4:30pm Eastern Time ROCKAWAY, N.J. , March 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2020 after
Toggle Summary electroCore to Participate at Two Upcoming Investor Conferences
ROCKAWAY, N.J. , March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming investor conferences. H.C. Wainwright Global Life Sciences Conference Format: pre-recorded